Table 7 List of countries in the Americas and their vaccine production capabilities as well as their share in the exportation market
From: Vaccine market and production capabilities in the Americas
| Country | Number of vaccines introduced in the EPI [74] | Vaccine produced in own facility | Local vaccine productiona (%) | Ranking in world exports of vaccines for human use [75] | bVaccine Type and target achieved [76] | |
|---|---|---|---|---|---|---|
| Antigua and Barbuda | 16 | 0 | 0 | No information reported |
HepB3 Hib3 IPV Pol3 DTP3 MCV2 MCV1 RCV1 |
99% 99% 99% 95% 95% 95% 93% 93% |
| Argentina | 26 | 9 | 34.62 | 49 |
MCV1 RCV1 BCG IPV MCV2 PCV3 HepB3 Hib3 DTP3 Pol3 RV YFV |
94% 94% 93% 90% 89% 88% 86% 86% 86% 84% 72% 8% |
| Bahamas | 22 | 0 | 0 | No information reported |
IPV Hep3 Hib3 PCV3 Pol3 DTP3 MCV1 RCV1 MCV2 RV |
91% 86% 86% 86% 86% 86% 86% 85% 82% 78% |
| Barbados | 15 | 0 | 0 | 63 |
IPV PCV3 MCV1 RCV1 Pol3 HepB3 Hib3 DTP3 MCV |
94% 93% 92% 92% 91% 90% 90% 90% 77% |
| Belize | 16 | 0 | 0 | No information reported |
IPV Hib3 Pol3 DTP3 MCV1 RCV1 BCG MCV2 HepB3 |
99% 98% 98% 98% 96% 96% 95% 95% 98% |
| Bolivia | 14 | 1 | 7.14 | No information reported |
IPV BCG MCV1 RCV1 RV YFV HepB3 Hib3 PCV3 Pol3 DTP MCV2 |
81% 80% 79% 78% 77% 75% 75% 75% 75% 75% 75% 44% |
| Brazil | 27 | 13 | 48.15 | 32 |
MCV1 RCV1 IPV Poli3 PCV3 RV HepB3 Hib3 BCG DTP3 YFV MCV2 |
91% 91% 86% 85% 84% 83% 80% 80% 79% 73% 60% 54% |
| Canada | 21 | 5 | 23.81 | 11 |
IPV Hib3 Pol3 DTP3 MCV1 RCV1 MCV2 PCV3 RV HepB3 |
94% 91% 91% 91% 90% 90% 87% 81% 79% 74% |
| Chile | 19 | 0 | 0 | No information reported |
IPV BCG HepB3 Hib3 Pol3 DTP3 MCV1 PCV3 RCV1 MCV2 |
99% 98% 96% 96% 96% 96% 95% 95% 95% 91% |
| Colombia | 22 | 3 | 13.64 | 54 |
MCV1 RCV1 PCV3 IPV HepB3 Hib3 Pol3 DTP3 RV BCG MCV2 YFV |
95% 95% 94% 93% 92% 92% 92% 92% 90% 89% 88% 87% |
| Costa Rica | 15 | 0 | 0 | 74 |
HepB3 IPV MCV1 PCV3 RCV1 DTP3 Hib3 Pol3 MCV2 BCG RV |
98% 96% 95% 95% 95% 95% 94% 94% 93% 88% 59% |
| Cuba | 16 | 9 | 56.25% | 43 |
BCG HepB3 Hib3 IPV MCV1 Pol3 RCV1 DTP3 MCV2 |
99% 99% 99% 99% 99% 99% 99% 99% 99% |
| Dominica | 14 | 0 | 0 | No information reported |
HepB3 Hib3 IPV Pol3 DTP BCG MCV1 RCV1 MCV2 |
99% 99% 99% 99% 99% 98% 92% 92% 92% |
| Dominican Republic | 18 | 0 | 0 | No information reported |
BCG IPV MCV1 RCV1 Pol3 DTP3 HepB3 RV Hib3 PCV3 MCV2 |
99% 98% 96% 96% 92% 89% 87% 80% 79% 70% 60% |
| Ecuador | 18 | 2 | 11.1 | No information reported |
BCG HepB3 Hib3 IPV Pol3 RV DTP3 YFV MCV1 PCV3 RCV1 MCV2 |
86% 85% 85% 85% 85% 85% 85% 84% 83% 83% 83% 76% |
| El Salvador | 19 | 0 | 0 | No information reported |
IPV Hib3 Pol3 DTP3 MCV1 RCV1 MCV2 BCG HepB3 PCV3 RV |
81% 81% 81% 81% 82% 82% 87% 78% 81% 82% 82% |
| Grenada | 14 | 0 | 0 | No information reported |
IPV HepB3 Hib3 MCV1 Pol3 RCV1 DTP3 MCV2 |
96% 94% 94% 94% 94% 94% 92% 82% |
| Guatemala | 18 | 0 | 0 | No information reported |
IPV Hib3 Pol3 DTP3 MCV1 RCV1 MCV2 PCV3 RV HepB3 |
90% 86% 79% 85% 90% 90% 78% 88% 86% 86% |
| Guyana | 16 | 0 | 0 | 81 |
BCG HepB3 Hib3 IPV RV DTP3 MCV1 PCV3 RCV1 Pol3 YFV MCV2 |
99% 99% 99% 99% 99% 99% 98% 98% 98% 97% 94% 92% |
| Haiti | 9 | 0 | 0 | No information reported |
IPV Pol3 BCG MCV1 RCV1 HepB3 Hib3 DTP3 RV PVC3 MCV2 |
78% 74% 73% 65% 65% 51% 51% 51% 48% 42% 41% |
| Honduras | 20 | 0 | 0 | No information reported |
IPV BCG RV HepB3 Hib3 MCV1 PCV3 Pol3 RCV1 DTP3 MCV2 |
90% 88% 88% 87% 87% 87% 87% 87% 87% 87% 85% |
| Jamaica | 16 | 0 | 0 | No information reported |
BCG IPV HepB3 Pol3 DTP3 Mcv1 RCV1 MCV2 |
97% 97% 96% 96% 96% 94% 94% 92% |
| Mexico | 20 | 7 | 35 | 35 |
IPV Hib3 Pol3 DTP3 MCV1 RCV1 MCV2 PCV3 RV HepB3 |
84% 82% 82% 82% 73% 73% 73% 86% 82% 56% |
| Nicaragua | 15 | 4 | 26.67 | 31 |
IPV MCV1 Pol3 RCV1 MCV2 BCG HepB3 Hib3 PCV3 RV DTP3 |
99% 99% 99% 99% 99% 98% 98% 98% 98% 98% 98% |
| Panama | 25 | 1 | 4 | 34 |
BCG MCV1 RCV1 MCV2 IPV PCV3 RV HepB3 Hib3 Pol3 DTP3 YFV |
99% 97% 97% 97% 96% 96% 94% 88% 88% 88% 88% 7% |
| Paraguay | 26 | 0 | 0 | No information reported |
YFV PCV3 IPV BCG MCV1 RCV1 HepB3 Hib3 RV DTP Pol3 MCV2 |
92% 89% 88% 87% 87% 87% 86% 86% 86% 86% 84% 83% |
| Peru | 20 | 0 | 0 | No information reported |
RV IPV HepB3 Hib3 DTP Pol3 MCV1 RCV1 BCG PCV3 MCV2 YFV |
90% 89% 88% 88% 88% 87% 85% 85% 81% 80% 66% 57% |
| Saint Kitts and Nevis | 13 | 0 | 0 | No information reported |
BCG MCV2 HepB3 Hib3 IPV MCV1 RCV1 Pol3 DTP3 |
99% 98% 97% 97% 97% 97% 97% 96% 96% |
| Saint Vincent and the Grenadines | 13 | 0 | 0 | No information reported |
BCG MCV1 Pol3 RCV1 MCV2 HepB3 Hib3 DTP3 IPV |
99% 99% 99% 99% 99% 97% 97% 97% 96% |
| Suriname | 17 | 0 | 0 | No information reported |
IPV HepB3 Hib3 DTP3 Pol3 MCV1 RCV1 MCV2 YFV |
82% 77% 77% 77% 76% 64% 64% 58% 57% |
| Trinidad and Tobago | 16 | 0 | 0 | 83 |
MCV1 RCV1 YFV HepB3 Hib3 PCV3 Pol3 DTP3 IPV MCV2 |
99% 99% 98% 93% 93% 93% 93% 93% 92% 92% |
| United States | 30 | 18 | 60 | 5 |
IPV Hib3 Pol3 DTP3 MCV1 RCV1 MCV2 PCV3 RV HepB3 |
97% 91% 93% 94% 90% 90% 95% 92% 74% 91% |
| Uruguay | 19 | 2 | 10.53 | No information reported |
BCG IPV MCV2 MCV1 RCV1 PCV3 HepB3 Hib3 DTP3 Pol3 |
99% 99% 99% 96% 96% 95% 94% 94% 94% 93% |
| Venezuela | 16 | 4 | 25 | No information reported |
MCV1 RCV1 BCG YFV HepB3 Hib3 DTP3 Poli3 IPV MCV2 |
93% 93% 91% 80% 64% 64% 64% 62% 55% 13% |